NDAOPHTHALMICOINTMENT
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOROPRYL (isoflurophate) is an ophthalmic ointment approved in 1957 for ocular conditions requiring cholinergic stimulation. It is a long-acting organophosphate compound that inhibits acetylcholinesterase, increasing parasympathetic activity in the eye. The drug is primarily used for glaucoma and accommodative esotropia management.
LOE Approaching
As LOE approaches, teams are typically focused on maximizing remaining market share and planning transition strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FLOROPRYL offers limited career growth potential given its mature, off-patent status and declining market relevance. Roles are concentrated in commercial sustainability, operations efficiency, and regulatory compliance rather than innovation, launch, or expansion.
Brand Manager (Legacy)Field Sales (Specialty Ophthalmology)
Worked on FLOROPRYL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.